
    
      Safety was assessed by the monitoring and recording of all adverse events (AEs), including
      drug hypersensitivity adverse events (DHAE), and serious adverse events (SAEs); clinical
      laboratory test (serum chemistry, hematology, urinalysis); tolerability (discontinuations,
      treatment delays, dose reductions); physical examinations (including vital signs assessment);
      12-lead electrocardiograms (ECG) obtained in triplicate and reviewed by independent blinded
      cardiologist, and Karnofsky's performance status.
    
  